












































Mutations in DNA repair genes, including breast cancer 
susceptibility 1 (BRCA1), are closely linked to the 
development of cancer. While mutations in BRCA1 are 
known to significantly increase the chances of 
developing breast and ovarian cancers, the mechanism 
behind this predisposition is not fully understood. Cells 
defective in BRCA1 are compromised in both major 
forms of DNA double-strand break (DSB)  repair  (non- 
 
 










































homologous end-joining (NHEJ) and homologous 
recombination repair (HRR)) as well as in cell cycle and 
transcriptional regulation [1-7]. This wide range of 
BRCA1 activities may be attributed to the association 
with numerous proteins part of the BRCA1-associated 
genome surveillance complex (BASC) [8-10]. Many of 
the proteins found in the BASC have known roles in the 
DNA damage response (DDR) and DSB repair and 
appear to have a dynamic relationship with BRCA1. As 

































Abstract:  We  introduced  a  K1702M  mutation  in  the  BRCA1  BRCT  domain  known  to  prevent  the  binding  of  proteins
harboring  pS‐X‐X‐F  motifs  such  as  Abraxas‐RAP80,  BRIP1,  and  CtIP.  Surprisingly,  rather  than  impairing  homologous
recombination repair (HRR), expression of K1702M resulted in hyper‐recombination coinciding with an accumulation of
cells in S‐G2 and no effect on nonhomologous end‐joining. These cells also showed increased RAD51 and RPA nuclear




BRCA1  RING  domain  (I26A)  known  to  reduce  BRCA1  ubiquitin‐ligase  activity.  These  in  vitro  findings  correlated  with
elevated nuclear RAD51 and RPA staining of breast cancer tissue from a patient with the M1775R mutation. Altogether, the
disruption  of  BRCA1  (BRCT)‐pS‐X‐X‐F  protein  binding  results  in  ubiquitination‐dependent  hyper‐recombination  via
excessive  DNA  resection  and  the  appearance  of  atypical  PML‐NBs.  Thus,  certain  BRCA1  mutations  that  cause  hyper‐
recombination instead of reduced DSB repair might lead to breast cancer.  
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repair factors and coordinate the temporal assembly and 
disassembly of proteins at the DSB necessary for 
efficient repair (for a recent review [11]). Therefore, it 
is no surprise that mutations in the BRCA1 gene affect 
the DDR in ways that lead to ineffective or faulty DNA 
repair.  
 
Most cancer-causing mutations within the BRCA1 gene 
have been found in the N- and C-terminal regions of the 
protein [12]. The N-terminal RING domain interacts 
with the BARD1 protein to form a hetero-dimeric 
complex with E3 ubiquitin-ligase activity. In addition, 
the BRCA1 C-terminal (BRCT) repeats are known to 
bind proteins having a unique phospho-serine motif 
(pS-X-X-F) that are involved in DNA damage 
checkpoint regulation and DSB repair [13-18]. It is 
believed that mutations within these regions result in 
loss of BRCA1 tumor suppressor function leading to 
genomic instability and, ultimately, the onset of breast 
and ovarian cancers [12, 19]. A functional link between 
the BRCA1 RING and BRCT domains was established 
with the finding that BRCA1-BARD1 ubiquitinates the 
BRCT-interacting protein CtIP resulting in CtIP-
mediated G2/M arrest and localization into DNA 
damage-induced foci [20]. However, the BRCT domain 
also binds the RAP80 ubiquitin-binding protein 
(through Abraxas), MERIT40, and other proteins that 
are not ubiquitinated such as the BRIP1 helicase, all of 
which are intimately associated with HRR [16-18, 21-
25]. It is now clear that BRCA1 plays a major role in 
the organization and assembly of proteins at DSBs, and 
this coordination is fine-tuned by SUMO (small 
ubiquitin-related modifiers) and ubiquitin post-
translational modifications to ensure efficient HRR [26-
29]. 
 
In the present study, we show that disruption of 
phospho-protein binding to the BRCA1 BRCT domain 
leads to hyper-recombination, perhaps as a result of 
excessive DNA resection. We further show disrupted 
binding increases ubiquitination of the BASC complex 
which is necessary for hyper-recombination. The 
naturally occurring BRCA1 BRCT mutant M1775R 
also produced unusual looking promyelocytic leukemia 
nuclear bodies (PML-NBs), suggesting M1775R upsets 
the normal processing of the BASC. Our results suggest 
that binding of repair proteins to the BRCT domain, 
together with timely (de)ubiquitination, is vital for 
correct spatiotemporal processing of DSBs and 
coordination of HRR. Thus, disruption of proper 
communication between proteins binding to the BRCT 
domain and ubiquitination may lead to increased 
genomic instability due to aberrant hyper-
recombination, and perhaps the onset of breast cancer.   
RESULTS 
 
K1702M induces hyper-recombination resulting 
from reduced binding to the BRCT domain  
 
To efficiently express full-length BRCA1 in HCC1937 
cells, which are a model cell system for elucidating 
BRCA1 function and are homozygous for the BRCA1 
5382insC mutation [30], we generated helper-dependent 
adenoviral (HD-Ad) vectors co-expressing BRCA1 and 
a LacZ reporter [31] (Figure 1A). The benefits of 
expressing BRCA1 from adenovirus are several-fold in 
that gene copy number and expression levels can be 
fully controlled without imposing possible cell selection 
and expression artifacts resulting from stable and 
transient expression from plasmids. To test the 
infectivity of HCC1937 cells, we performed β-
galactosidase (LacZ) staining and found high levels of 
infection efficiency (Figure 1B). We also confirmed 
expression of full-length BRCA1 by western blot 
analysis and found that it migrated slightly above the 
endogenous, truncated BRCA1 protein (erroneous 
translation distal to codon 1755) produced by HCC1937 
cells (Figure 1C). The level of endogenous, truncated 
BRCA1 to virus-expressed BRCA1 was similar (2.6-
fold above endogenous), which is critical since too 
much BRCA1 expression could possibly offset desired 
reconstituted effects. These results show that HD-Ad 
vectors infect HCC1937 cells with high yield and 
express full-length BRCA1 transiently at close to 
physiological levels.  
 
Having demonstrated BRCA1 expression using the HD-
Ad vector system, we next determined the effect of 
BRCA1 on HRR in HCC1937 cells using the green 
fluorescent protein (GFP)-based I-SceI assay [32-34]. 
We found that BRCA1 significantly increased HRR 
almost 4-fold compared to vector control infected cells, 
which showed repair levels similar to those of 
uninfected cells (Figure 1D). These results demonstrate 
that the DSB repair defect of HCC1937 cells can be 
rescued by BRCA1 expressed from HD-Ad, in line with 
previous reports [1, 35]. 
 
The K1702 residue resides within the binding pocket of 
the BRCA1 BRCT domain and interacts directly with 
the phospho-serine moiety of pS-X-X-F motif 
containing proteins that bind to the pocket [36]. Thus, 
we expected that the K1702M mutation would result in 
decreased binding of BRCT interacting proteins such as 
CtIP, which served as an indicator of the ability of this 
mutant to bind any phospho-protein in our study. 
Plasmids expressing wild-type or K1702M BRCA1 
were co-transfected with a plasmid expressing CtIP into 
HEK293T cells followed by immuno-precipitation of 
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BRCA1 bound CtIP efficiently (Figure 2A). We also 
noticed an increase in the abundance of BRCA1 and 
CtIP when co-expressed compared to either alone, 
suggesting that complex formation increases the 
stability of these two proteins. When we examined 
binding of CtIP to K1702M, we found at least a 10-fold 
reduction compared to wild-type BRCA1 (Figure 2B). 
These results demonstrate that the K1702M mutation 
disrupts the binding of CtIP in vivo, which is consistent 
with  in vitro binding studies of peptides [36, 37]. 
Presumably, this disruption also extends to other 
phospho-proteins that normally bind the BRCA1 BRCT 
domain. Thus, the K1702M phenotype would be a 
reflection of the inability of any pS-X-X-F protein to 
bind BRCA1 and influence DSB repair. 
 





































the BRCA1 BRCT domain is known to interact with 
CtIP, BRIP1, and Abraxas-RAP80, which are all 
involved in HRR [16-18, 21, 22, 38], we expected to see 
a decrease in HRR with K1702M. Surprisingly, we 
found that K1702M significantly increased HRR >3-
fold compared to wild-type BRCA1 (Figure 2C). In 
addition, when we examined what effect K1702M 
might have on NHEJ levels at a separate locus, we 
found that NHEJ increased 2-fold, similar to cells 
infected with wild-type BRCA1 virus (Supplemental 
Figure S1). This result suggests that the effect of 
K1702M on DSB repair is HRR-specific. Curiously, 
K1702M hyper-recombination did not increase the 
radiosurvival of HCC1937 cells, whereas wild-type 
BRCA1 did (Supplemental Figure S2). In fact, K1702M 
cells were more radiosensitive than wild-type BRCA1 
cells, even though expression levels were similar 











































expression  after  infection  with  HD‐Ad  vector  control  or  wild‐type  BRCA1  (BRCA1
wt)  or  with  uninfected
HCC1937 cells. (C) Western blot analysis of lysates from HCC1937 cells infected as in B probed with FLAG
(HD‐Ad  BRCA1)  and  BRCA1  (HD‐Ad  BRCA1  +  endogenous  5382insC  BRCA1)  antibodies.  Arrows  indicate
protein bands related to endogenous 5382insC BRCA1. (D) HCC1937/DR‐GFP cells were infected with the
indicated HD‐Ad vectors or left uninfected followed by infection with Ad‐SceI and HRR/GFP events were
analyzed  by  fluorescence‐activated  cell  sorting  (FACS).  Error  bars  show  SEM  from  three  independent
experiments (**, P < 0.01). P = 0.0017 when wild‐type BRCA1 was compared to vector control. 
   






































To further investigate the underlying cause of K1702M-
mediated hyper-recombination, we determined whether 
this mutant had any effect on cell-cycle distribution. We 
found that K1702M resulted in almost a 3-fold increase 
of cells in the G2/M phases, and a corresponding 
decrease in the G1 phase, over a 48 hour time period 
compared to wild-type BRCA1 (Supplemental Figure 
S3). In addition, there were little to no differences in the 
cell cycle profile between vector control and wild-type 
BRCA1 infected cells. Because HRR occurs 
predominantly, if not exclusively, in late S and G2 [39, 
40], these cell cycle perturbations as well as decreased 
radiosurvival suggest a possible defect in HRR of 
spontaneous and radiation-induced DSBs in cells 
expressing the K1702M mutant. Thus, deregulated HRR 
in cells with reduced binding of phospho-proteins to 







































DR-GFP assay, could be more of an impediment for cell 
survival than a null mutation of a HRR gene, perhaps as 
a result of aberrant recombination events. 
 
K1702M increases RAD51 nuclear staining that co-
localizes with RPA  
 
To determine whether the hyper-recombination 
observed with K1702M in the site-specific DR-GFP 
assay reflected an overall increase in HRR in the cell, 
we next examined RAD51 foci formation in irradiated 
cells. RAD51 is uniquely utilized in HRR and the 
appearance of RAD51 foci indicate repair centers 
engaged in HRR [41]. In support of the results seen 
with the DR-GFP assay, without any irradiation 
K1702M expressing cells showed significant ~30-fold 
higher levels of RAD51 nuclear staining than cells 






wt  or  K1702M  were  co‐transfected  with  Myc‐CtIP  and  immuno‐precipitated  FLAG  material  was
examined for CtIP binding as in A. (C) HCC1937/DR‐GFP cells infected with the indicated HD‐Ad vectors or left
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only an ~1.5-fold further increase was observed with 
K1702M cells after irradiation. This result suggests that 
spontaneous DSBs, e.g., lesions generated during 
replication, could account for a large proportion of the 
increased RAD51 nuclear staining in K1702M cells. 
Interestingly, western blot analysis showed no increase 
in the overall levels of RAD51 in lysates from K1702M 
compared to those from cells expressing wild-type 
BRCA1 (Supplemental Figure S4). This result suggests 
it is the localization of RAD51 at defined DNA sites 
that is enhanced rather than the overall level of RAD51 
expression when K1702M is expressed. Altogether, 
these results suggest that K1702M promotes the 
generation of extensive RAD51 filaments regardless of 
exogenous DNA damage, a finding that is in line with 







































When a DSB is processed for repair by HRR, the 5' 
DNA ends are resected to provide 100-200 nucleotides 
or more of 3' DNA overhangs suitable for strand-
invasion, Holliday junction formation, and the 
completion of repair [42]. To determine whether 
K1702M expression might increase ssDNA formation, 
we examined whether RPA co-localized with RAD51 in 
these cells. RPA binds to ssDNA and stabilizes 
Holliday junction intermediates. Indeed, RPA was 
found to co-localize with RAD51, which increased after 
irradiation in both BRCA1 wild-type and K1702M 
infected cells (Figure 3B). However, the tremendous 
increase in nuclear RAD51 in a sub-population of 
K1702M cells overwhelmed the RPA staining making it 
impossible to determine whether co-localization 
occurred or not. These results support the notion that 
K1702M promotes extensive ssDNA formation that 

















































































K1702M increases ubiquitination of the BASC 
necessary for hyper-recombination  
 
As BRCA1 is known to ubiquitinate CtIP [20], we 
determined the effect of decreased CtIP binding on 
ubiquitination of the BASC and the functional link 
between BASC ubiquitination and HRR using an 
I26A/K1702M double mutant. The BRCA1 I26A 
ubiquitin-ligase mutant is known to prevent the 
interaction of BRCA1 with the E2 ubiquitin-conjugase 
while still binding BARD1 [43]. We found that the 
double mutant significantly diminished hyper-
recombination compared to the K1702M single mutant 
when BRCA1 expression levels were similar (Figure 
4A, B). In addition, we did not observe a significant 
difference in HRR between wild-type BRCA1 and the 
I26A single mutant in agreement with a previous report 
[44]. To determine whether diminished hyper-





































tination, plasmids expressing different BRCA1 forms 
were co-transfected with a plasmid expressing Myc-
tagged ubiquitin into HEK293T cells. We found that 
K1702M increased ubiquitination of the BASC ~1.5-
fold compared to wild-type BRCA1 (Figure 4C). As 
expected, I26A showed decreased (~0.7-fold) 
ubiquitination of the BASC but retained the ability to 
bind CtIP at levels similar to wild-type BRCA1, 
whereas the double mutant displayed a similar defect in 
CtIP binding as the K1702M single mutant (Figure 4C, 
D). Our results show that hyper-recombination requires 
a ubiquitination-dependent interaction between the 
BRCA1 RING and BRCT domains, a process that is 
enhanced when phospho-proteins are unable to bind to 
the BRCT domain. Altogether, these results suggest that 
BASC ubiquitination correlates with hyper-
recombination and is dominant over the BRCT-
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staining in part co-localizing with ssDNA but not 
with atypical PML nuclear bodies   
 
M1775R is a recurring deleterious BRCA1 mutation 
and one of the first reported missense mutations of 
BRCA1 [45-47]. The M1775R mutation prevents 
phospho-protein binding by sterically clashing with the 
phenylalanine ring of the pS-X-X-F motif as opposed to 
K1702M, which disrupts the electrostatic interaction of 
K1702 with the phospho-serine of the motif [36, 37, 
48]. Previous studies have suggested that M1775R is 
impaired in nuclear localization and foci formation [36, 
49, 50]. Therefore, we first examined whether BRCT 
mutants expressed from the HD-Ad vectors were able to 
enter the nucleus of HCC1937 cells. K1702M showed 
enhanced nuclear localization compared to wild-type 
BRCA1, regardless of irradiation (Figure 5A). In 
addition, M1775R also entered the nucleus but seemed 
to remain around the nuclear membrane. To substantiate 
this result, we conducted a cell fractionation experiment 
followed by western blotting and found that most of 
M1775R was indeed located in the nuclear fraction with 
some protein remaining in the cytoplasm, while there 
was little to no detectable wild-type BRCA1 in the 
cytoplasm regardless of whether cells were irradiated or 
not (Figure 5B). In the nuclear fraction, wild-type 
BRCA1 had slower electrophoretic mobility than 
M1775R, suggesting that the wild-type protein was 
more heavily modified than the mutant. These results 
suggest that while there may be some impairment to 
M1775R nuclear localization as previously reported 
[36, 49, 50], significant levels of BRCA1 BRCT mutant 
proteins were present in the nucleus following their 
expression from HD-Ad vectors, which would be 
necessary to influence HRR.  
 
M1775R also demonstrated a much reduced ability to 
bind CtIP and produced elevated levels of RAD51 and 
RPA nuclear staining compared to wild-type BRCA1 
when BRCA1 expression levels were similar, all of 
which were not dependent on exogenous DNA damage 
(Figure 6A-D). In fact, M1775R induced the formation 
of what appeared to be large, clustered RPA foci. To 
determine whether the increased nuclear RAD51 and 
RPA staining was indeed the result of increased ssDNA 
engaged in recombination, we examined the extent of 
ssDNA formation by an assay that utilizes BrdU 
incorporation into DNA [41]. Indeed, M1775R cells 
showed elevated levels of ssDNA that to some extent 
co-localized with the large clusters of RPA foci 
compared to the much smaller co-localized foci seen in 
wild-type BRCA1 cells (Figure 6E). Furthermore, in 
cells expressing wild-type BRCA1, RPA was 












































bodies (NBs) whereas cells expressing M1775R showed 
highly unusual, thread-like PML-NBs that did not co-
localize with RPA (Figure 6F). PML-NBs are believed 
to be nuclear compartments for post-translational 
processing such as (de)SUMOylation and 
(de)ubiquitination and the (de)assembly of protein 
complexes critical for transcription and DNA repair [51, 
52]. Recently, it was shown that SUMOylation is 
important for efficient HRR [28, 29]. Thus, the 
appearance of atypical, thread-like PML-NBs in 
M1775R but not wild-type BRCA1 expressing cells 
suggests that M1775R promotes the generation of these 
Figure  5.  BRCA1  BRCT  mutants  expressed  from  HD‐Ad
vectors  enter  the  nucleus  of  HCC1937  cells.  (A)  HCC1937
cells infected with the indicated HD‐Ad vectors were examined for
BRCA1 nuclear localization by FLAG immuno‐staining after 4 Gy






www.impactaging.com                   521                                             AGING,    May 2011, Vol.3 No.5abnormal PML-NBs. All combined, the naturally 
occurring M1775R mutant generated a similar, if not 



















































of RAD51 and RPA nuclear staining, but also showed 
evidence of extensively resected DNA and unusual 




























































with  DNA‐PKcs  as  loading  control.  (E)  RPA  and  ssDNA  co‐staining  of  representative  HCC1937  cell  nuclei





























M1775R increases nuclear RAD51 and RPA staining 
in human breast cancer tissue  
 
We next determined whether our in vitro results would 
translate into effects seen in human breast cancer tissue. 
Sections from patients with various BRCA1 mutations, 
including M1775R and C64G (reported to have a 
similar defect in ubiquitin-ligase activity as the 
synthetic I26A mutation [43]), and patients with normal 
BRCA1 breast tumors were examined. Consistent with 
our  in vitro data, the M1775R tissue section showed 
increased RAD51 and RPA staining in nuclear 
malignant regions (Figure 7; Supplemental Table S1). 
In fact, the RPA levels in M1775R were the highest of 
all the sections and similar to those of a ductal 
carcinoma  in situ (DCIS) section (WT-DCIS). 
However, the M1775R section did not show any 
detectable BRCA1 staining, similar to the R1443X and 
943ins10 sections. This result suggests that M1775R is 
down-regulated, perhaps due to toxicity and/or 
instability in vivo as reported in vitro [53]. This finding 
implies that considering the relatively low expression, 
M1775R results in very high relative levels of RAD51 
and RPA if these are dependent on BRCA1 compared to 
those seen with either the R1443X or 943ins10 sections 
that also had low BRCA1 expression. On the other hand 
C64G, which is known to increase the stability of 
BRCA1 by oligomerization [54], showed high levels of 
RAD51, RPA, and BRCA1. Thus, the level of BRCA1 
expression should be taken into consideration when 

























on the high expression of RAD51 and RPA relative to 
low M1775R expression, these results suggest that 
M1775R may promote excessive HRR in vivo as has 
been suggested to occur in some breast cancers with 
low BRCA1 levels [55]. However, more tissues with 
BRCT mutations need to be screened before such an 
assertion could be made significant. We also observed 
elevated levels of RAD51 and RPA staining in a DCIS 
tissue section with wild-type BRCA1 that showed 
increased BRCA1 expression relative to malignant 
tissue. DCIS is commonly associated with non-invasive, 
pre-malignant breast cancer. Thus, the data presented 
here could perhaps have clinical implications in that 
RAD51 and RPA might be useful diagnostic markers 
for pre-malignant (DCIS) breast cancers and, in 
particular, for screening breast cancers for mutations in 





In this study, we examined the ability of synthetic and 
natural BRCA1 BRCT mutants to modulate DSB repair. 
As a surrogate for determining protein binding to the 
BRCT domain, we used CtIP which is known to bind 
BRCA1 efficiently when phosphorylated at S327 [56]. 
However, it is presumed that these BRCT mutants 
would not bind any protein with a pS-X-X-F motif, also 
including Abraxas-RAP80, BRIP1, and MERIT40 [11]. 
As expected, we found that both the K1702M and 
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expressing these BRCT mutants displayed hyper-
recombination by the DR-GFP assay and increased 
RAD51-RPA-ssDNA nuclear staining, indicative of 
elevated levels of recombination intermediates. There is 
precedence for BRCA1-associated hyper-recombination 
as several recent reports suggest that the disruption or 
depletion of specific BRCA1-interacting proteins results 
in hyper-recombination [57-59]. Our results further 
show that cells expressing BRCT mutants accumulate in 
G2 and require ubiquitination for hyper-recombination. 
BRIP1 is believed to mainly function in S and not be 
dependent on ubiquitination [60], whereas Abraxas-
RAP80 and CtIP function primarily in G2 and depend 
on ubiquitination [17, 20]. Of the three better 
characterized BRCT binding partners (Abraxas-RAP80, 
BRIP1, and CtIP), we favor the disruption of Abraxas-
RAP80 and CtIP binding to BRCA1 as basis for the 
hyper-recombination we observe in our study. 
 
A similar stimulation of HRR to what we see with 
BRCT mutants was recently demonstrated when either 
Abraxas, RAP80, or BRCC36 was depleted [58, 59]. It 
was proposed that the role of the BRCA1-Abraxas-
RAP80-BRCC36 complex is to limit DSB resection. 
Thus, disruption of this complex by certain BRCA1 
BRCT mutations may lead to further resection mediated 
by CtIP or other nucleases. CtIP has important roles in 
both HRR and NHEJ, and based on its similarity to the 
yeast Sae2 protein, which harbors nuclease activity 
toward a variety of defined repair substrates in vitro, 
CtIP acts as both an adaptor and nuclease in mammalian 
DSB processing [38, 61]. Silencing CtIP or expression 
of a S327A mutant unable to bind BRCA1 impairs HRR 
[38]. BRCA1 also associates with the MRE11-RAD50-
NBS1 (MRN) complex [62], and BRCA1-CtIP-NBS1 
form a complex in a cell-cycle dependent manner [23].  
In addition, in human cells Exo1 works together with 
CtIP and MRN to resect the DSB [63]. Thus, it might be 
the improper function of the BRCA1-Abraxas-RAP80 
complex, combined with untamed CtIP, MRN, and/or 
Exo1 resection that leads to the generation of more 
extensive ssDNA at the DSB in our study.  
 
It is important to point out that the increased HRR we 
see with the DR-GFP assay is likely a reflection of an 
increased rate by which Holliday junctions are formed 
and remain present rather than an increased number of 
DSBs becoming available for processing. The single 
I-SceI target site is likely cleaved to the same extent 
regardless of BRCA1 status, and the K1702M mutation 
did not appear to change the fraction of breaks being 
channeled into NHEJ in agreement with one study [58], 
but in disagreement with another [59]. The reason for 
these dissimilarities is unclear but could be explained by 
differences in experimental system or cell cycle effects. 
In our study, when K1702M was expressed we noticed 
an accumulation of cells in G2 where HRR is 
particularly active. Thus, excessive DNA resection 
could accelerate progression to the later stages of HRR 
which may be the main contributing factor to the faster 
accumulation of GFP+ cells we see with the K1702M 
mutant. 
 
We also found that K1702M increased ubiquitination of 
the BASC, and that ubiquitination was necessary for 
hyper-recombination but did not affect the ability of 
wild-type BRCA1 to stimulate HRR. It was recently 
shown that the BRCA1 I26A ubiquitin-ligase mutant 
did not affect HRR and mitomycin C survival of mouse 
embryonic stem cells [44], which is consistent with our 
results. Thus, ubiquitination is necessary for hyper-
recombination in the context of altered BRCT 
interactions to compensate for the loss of normal repair 
activity associated with BRCA1 complexes. It is 
tempting to speculate that BRCC36, part of the 
Abraxas-RAP80 complex and a putative deubiquitinase 
[24], perhaps cannot deubiquitinate the BASC, resulting 
in an accumulation of ssDNA intermediates and RPA-
RAD51-DNA complexes unable to turn over. 
Therefore, increased DSB resection could be the result 
of a failure of BRCT mutants to support the progression 
of repair past resection due to the inability of BRCC36, 
or other deubiquitinase, to process late-stage repair 
complexes. Ubiquitination of chromatin necessary for the 
binding of BRCA1 to DSBs through Abraxas-RAP80 is 
required early in the DDR [16-18]. Therefore, we favor 
the idea that BRCT mutants are able to overcome this 
early blockade. Instead, it seems it is a later stage of the 
repair process following DNA resection, which is also 
critically ubiquitination-dependent, that primarily 
contributes to hyper-recombination. 
 
Promyelocytic leukemia nuclear bodies (PML-NBs) are 
important for the assembly and disassembly of protein 
complexes, including those with RAD51, RPA, and 
BRCA1 necessary for HRR (for a recent review [51]). 
The finding that M1775R promoted clustered RPA foci 
that in part co-localized with ssDNA but not with the 
atypical PML-NBs is interesting. If (de)SUMOylation-
(de)ubiquitination is necessary for the spatiotemporal 
processing of HRR complexes that might occur in or in 
close proximity to PML-NBs [51, 52], this suggests that 
M1775R is upsetting some step after Holliday junction 
formation resulting in the creation of these unusual 
PML-NBs. Atypical PML-NBs may be a manifestation 
of altered (de)ubiquitination of the BASC as discussed 
above. What is presently not clear is whether the cells 
with clustered RPA foci and atypical PML-NBs 
represent a temporary accumulation of intermediates in 
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or whether these cells are irreversibly ‘stuck’ in the 
repair process. Thus, certain BRCT mutants might upset 
the spatiotemporal ‘handing-over’ processes controlled 
by (de)ubiquitination which is seen as an accumulation 
of late repair intermediates and hyper-recombination. 
 
To date, little is known about how pathogenic BRCA1 
mutations that disrupt BRCT phospho-protein binding 
affect DSB repair and the pathophysiology of breast 
cancer [55, 64]. The results from our limited analysis of 
breast cancer tissues, including one from a patient with 
the M1775R mutation, are in line with our in vitro 
findings and the notion that RAD51 and RPA foci 
levels are elevated in cells that express M1775R. It was 
previously reported that some BRCA1-deficient breast 
tumors have enhanced HRR [55]. However, the germ-
line BRCA1 statuses of these samples were not identified. 
The results presented here help explain how BRCA1 
BRCT mutations might contribute to breast cancer 
through a mechanism involving increased, and most 
likely aberrant, HRR rather than through the loss of 
BRCA1 function and reduced HRR. In fact, our 
radiosurvival experiment suggests that K1702M 
radiosensitizes cells rather than just fails to rescue 
radiosensitivity. Similar conclusions were also made to 
explain genomic instability and increased radiosensitivity 
of cells that were depleted of RAP80, Abraxas, or 
BRCC36 [58, 59]. Our results are complementary to 
these recent findings and recapitulate hyper-
recombination with specific BRCT mutants (one of them 
naturally occurring) unable to bind critical proteins, and 
link genomic instability with ubiquitination-dependent 
processing that occurs late in HRR. Most importantly, we 
have demonstrated that the correct temporal and physical 
interactions between BRCA1 and these proteins are 
critical for maintaining normal HRR and preserving 
genomic stability. Our results have implications for the 
development of potential inhibitors disrupting BRCT 
interactions. Such inhibitors might actually stimulate 
HRR and lead to cell-cycle arrest with relatively little 
impact on the radiosurvival of tumor cells with normal 
BRCA1. On the other hand, the finding that 
ubiquitination dominates over the BRCT-mediated 
effects resulting in hyper-recombination suggests that 
targeted inhibition of BRCA1 ubiquitin-ligase activity or 
enhancing deubiquitination could be more effective for 
interfering with BRCA1-mediated DSB repair in BRCT 
mutant cells. Thus, caution should be exercised when 




Cell culture. HCC1937 cells were cultured at 37ºC in 
RPMI-1640 (Cellgro), and HEK293-116C and 
HEK293T cells in DMEM (Gibco) medium 
supplemented with 10% FBS and antibiotics.    
 
Plasmids. QuikChange site-directed mutagenesis 
(Stratagene) was used to create mutations from wild-
type (wt) BRCA1 plasmid pcDNA3(BssHII)-HA-
3XFLAG-BRCA1. The K1702M mutation was created 
using primers 5'-GTGAACGGACACTGATGTATTTT 
CTAGGAATTG-3' and 5'-CAATTCCTAGAAAATAC 
ATCAGTGTCCGTTCAC-3'. The I26A mutation was 
created using primers 5'-CTTAGAGTGTCCCGCCTG 
TCTGGAGTTG-3' and 5'-CAACTCCAGACAGGCGG 
GACACTCTAAG-3'. The M1775R mutation was 
created using primers 5'-TATGGGCCCTTCACCAAC 
AGACCCACAGATCAACTGG-3' and 5'-CCAG 
TTGATCTGTGGGTCTGTTGGTGAAGGGCCCATA
-3'. Additional plasmids used were pcDNA3-5XMyc-
CtIP and pCMV-Myc-ubiquitin [65, 66]. 
 
Generation of HD-Ad vectors. Plasmids 
pcDNA3(BssHII)-HA-3XFLAG-BRCA1 wt, K1702M, 
I26A, I26A/K1702M, and M1775R were digested with 
BssHII and the HA-3XFLAG-BRCA1 fragments ligated 
into the AscI site of the helper-dependent adenovirus 
(HD-Ad) plasmid pΔ28E4LacZ [31]. The pΔ28E4LacZ-
HA-3XFLAG-BRCA1 plasmids were digested with 
PmeI to release the viral DNA from the plasmid 
backbone. The viral DNA was packaged into 
adenovirus and amplified by transfecting HEK293-
116C cells using Superfect (Qiagen) as described [31]. 
 
Antibodies. Antibodies used were FLAG (M2; Sigma), 
BRCA1 (Ab-1; Calbiochem), Myc (9B11; Cell 
Signaling), RAD51 (Ab-1; Calbiochem), DNA-PKcs 
(4F10C5; Biosource), RPA/p32 (Ab-1; NeoMarkers), 
BrdU (BU1/75 (ICR1); Abcam), PML (H-238; Santa 
Cruz Biotechnology), and Actin (I-19; Santa Cruz 
Biotechnology). 
 
Western blotting and immuno-precipitation. All cellular 
material was prepared 48 h after plasmid transfection or 
HD-Ad infection and proteins were separated by SDS-
PAGE for western blot analysis. Total cell lysates were 
prepared in RIPA buffer with protease and phosphatase 
inhibitors (Sigma) and PMSF. For immuno-
precipitation experiments, recombinant HA-3XFLAG-
BRCA1 protein from HEK293T cells transfected with 
pcDNA3(BssHII)-HA-3XFLAG-BRCA1 plasmids 
using polyethylenimine (Polysciences, Inc.) was 
immuno-precipitated with anti-FLAG M2 beads 
(Sigma) in 0.5X RIPA buffer/0.5X PBS with inhibitors. 
For cell fractionation, cell pellets were treated with a 
0.5% Triton X-100 lysis buffer to release cytoplasmic 
proteins followed by centrifugation (2,000 rpm) and 
nuclei were washed in lysis buffer and PBS followed by 
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nuclear buffer for 30 min and centrifuged for 30 min at 
10,000 rpm. Volumes were adjusted to give equal 
portions of cytoplasmic and nuclear fractions. Protein 
was imaged and quantified using the Odyssey Infrared 
Imaging System and application software version 3.0 
(Li-Cor Biosciences). 
 
DNA repair assay.  The HRR-GFP repair system has 
been described previously [33, 34]. HCC1937 cells 
were stably transfected with the DR-GFP repair plasmid 
[32], and selected in puromycin. HCC1937/DR-GFP 
cells at ~90% confluency were serum-starved and 
infected with HD-Ad vectors. Forty-eight hours after 
HD-Ad infection, cells were infected with an 
adenovirus expressing the endonuclease I-SceI (Ad-
SceI) and repair events determined at either 48 or 72 h 
after Ad-SceI infection by GFP fluorescence-activated 
cell sorting (FACS) as described [33, 34].  
 
Immunocytochemistry. HCC1937 cells were seeded 
onto 4-well chamber slides and infected with HD-Ad 
vectors. Forty-eight hours after infection, cells were 
irradiated with 4 Gy using a Gammacell 40 Exactor 
(MDS Nordion) or left unirradiated, fixed with 3% 
paraformaldehyde, permeablized with 0.5% Triton X-
100, immuno-stained, and counterstained with DAPI. 
For RAD51 and RPA staining, cells were fixed 8 h after 
irradiation. For RAD51 quantification, cells were 
imaged using the Applied Imaging Ariol (Genetix) at 
40x magnification and images were quantified using 
CellProfiler cell image analysis software (Broad 
Institute) (http://www. cellprofiler.org/). Other 
experiments were imaged using a Zeiss LSM 510 
META confocal laser scanning microscope at 63x 
magnification. For BRCA1 nuclear-cytoplasmic 
localization studies, cells were fixed and stained with 
FLAG antibody 4 h after irradiation. For ssDNA 
detection, cells were labeled with 30 µM BrdU 48 h 
prior to infection. Cells were then pre-extracted in 
buffer containing 100 mM NaCl, 1 mM EDTA, 3 mM 
MgCl2, 300 mM sucrose, and 0.5% Triton X-100 prior 
to fixation, and permeabilized with 0.5% Triton X-100 
to detect the yield of BrdU incorporation and ssDNA. 
Cells were immuno-stained with anti-BrdU antibody 
[41], and imaged using a Leica TCS-SP2 AOBS 
confocal laser scanning microscope at 63x 
magnification. Parallel cultures were checked for total 
BrdU incorporation by also including a 2N HCl step 
followed by neutralization with 0.1 M Borax as 
recommended by the manufacturer. 
 
Selection, randomization, and blinding of human breast 
cancer tissues. Patients with constitutional BRCA1 
mutations were identified among all patients seen 
through the Clinical Genetics Service at Virginia 
Commonwealth University Health System. Since clinical 
BRCA1 testing is exclusively available through Myriad 
Genetics Laboratories, Inc., Myriad provided the Clinical 
Genetics Service with a list of patients who were tested 
for BRCA1 mutations up until September 2009. Medical 
records for patients with deleterious mutations were 
accessed by the genetic counselor in the clinical 
department to verify results and identify the specific 
mutations for these individuals. Technical specifications 
for  BRCA1 testing through Myriad is available 
(http://www.myriadtests.com/provider/doc/BRACAnaly
sis-Technical-Specifications.pdf). Clinic notes were also 
queried and one patient with a BRCA1 M1775R 
mutation was identified whose testing was performed 
through Fox Chase Cancer Center as part of a research 
study. Medical record numbers of all patients (without 
mutation status) were sent to the study pathologist to 
identify patients for whom breast cancer tissue was 
available. The genetic counselor then assigned a study 
identification number to each patient with available 
tissue. From this list the genetic counselor selected all 
patients with deleterious mutations and available tissue 
(n = 4) along with two randomly selected patients 
among those without identified BRCA1 mutations. The 
medical record numbers were then sent to the 
pathologist. Results were sent back to the genetic 
counselor at which time the data were stripped of their 
medical record numbers and identified only with the 
study identification number. In this way all investigators 
except the genetic counselor were blinded to the 
mutation status during tissue analysis and only the 
clinical pathologist and genetic counselor had access to 
patient identifiers. All procedures were approved by the 
VCU IRB (protocol #HM12581). 
 
Immunohistochemistry of human breast cancer tissues. 
Sectioning of tissue and antigen retrieval was performed 
by Anatomic Pathology Research Services, Department 
of Pathology, Virginia Commonwealth University. 
Briefly, slides were each de-paraffinized through 3 
changes of xylene for 5 min and rehydrated through 2 
changes of 100% reagent ethyl alcohol for 3 min, 1 
change of 95% for 3 min, and 1 change of 80% for 3 
min. Endogenous peroxidase activity was blocked by 
incubation in 0.3% hydrogen peroxide at room 
temperature for 5 min. Antigen retrieval was performed 
using Heat Induced Epitope Retrieval (HIER) consisting 
of a 20 min incubation in Target Retrieval Solution, pH 
6 (Dako Corporation) and a 20 min cooling period. 
Sections were blocked with 10% normal goat serum in 
PBS/0.01% Triton X-100 for 1 h at room temperature. 
Primary antibodies RAD51 (1:1000), RPA/p32 (1:500), 
and BRCA1 (1:200) in Antibody Diluent with 
Background Reducing Agents (Dako Corporation) were 
   
www.impactaging.com                   526                                            AGING, May 2011, Vol.3 No.5added to sections and incubated overnight at 4 ºC. After 
washing with PBS/0.01% Triton X-100, sections were 
incubated with Envision+
TM Dual Link (Dako 
Corporation) conjugated to HRP for 1 h at room 
temperature, washed again, and exposed to DAB+ 
(diaminobenzidine) (Dako Corporation) briefly while 
monitoring for the development of brown staining. 
Slides were then rinsed in water for several min before 
counterstaining with Gills III Hematoxylin (Poly 
Scientific). Sections were dehydrated with sequential 
washes in 70%, 95%, and 100% ethanol and finally 
incubated in Histoclear. Coverslips were then mounted 
over the sections with Permount (Sigma). Images of 
representative areas of the tumors were taken using a 
Nikon ACT-1 camera at 400x magnification. 
 
Statistics. Unpaired two-tailed t-tests were performed 
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cells  in  S  and  G2.  HCC1937  cells  infected  with  the






Supplemental  Figure  S2.  K1702M  increases  the 
radiosensitivity  of  HCC1937  cells.  HCC1937  cells  infected 
with  the  indicated  HD‐Ad  vectors  or  left  uninfected  were 
irradiated with either 4 or 8 Gy and counted by FACS after the 
addition  of  Trypan  Blue.  Error  bars  show  SEM  from  three 
independent experiments (**, P < 0.01). P = 0.0022 and 0.0047 
when  vector  control  was  compared  to  wild‐type  BRCA1  and 
K1702M at 8 Gy, respectively. 
Supplemental  Figure  S4.  K1702M  does  not  increase
RAD51  expression  levels.  Western  blot  analysis  of  RAD51
from  lysates  of  HCC1937  cells  48  h  after  infection  with  the
indicated HD‐Ad vectors. Actin was used as a loading control.  
   

























49  R1443X 2+  1+  2-3+  2+  Previous biopsy related changes and 
fat necrosis excluded 
35 M1775R  2+ 2+ 1+ 2+ Macrophages  and  fat  necrosis 
excluded (previous biopsy site) 
15  negative NA  2+  NA  2+  Only DCIS, no benign and no 
invasive carcinoma 
5  negative 1+  1+ 2+ 1+ Focal  sclerosing  adenosine;  edge 
effect avoided 
23  C64G NA  2-3+  NA  2-3+  No benign breast in section 















49  R1443X 1+  2+  0  0  Previous biopsy related changes and 
fat necrosis excluded 
35 M1775R  2+ 3+  0  0  Macrophages and fat necrosis 
excluded (previous biopsy site) 
15  negative 2+  3+  0  0  Only DCIS, no benign and no 
invasive carcinoma 
5  negative 0  1+  0  0  Focal sclerosing adenosine; edge 
effect avoided 
23  C64G NA  2+  NA  0  No benign breast in section 
57  943ins10 0  1+ 
<5% 



















0  Previous biopsy related changes and 
fat necrosis excluded 
35 M1775R  0  0 0 0 Macrophages  and  fat  necrosis 
excluded (previous biopsy site) 








Only DCIS, no benign and no 
invasive carcinoma 




Focal sclerosing adenosine; edge 
effect avoided 
23  C64G NA  2+  NA  1+  No benign breast in section 
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Supplemental Table S1. Pathologist's analysis of human breast cancer tissue sections.  SUPPLEMENTAL METHODS 
 
NHEJ assay. The NHEJ-DsRed system uses a lentiviral 
DNA cassette stably integrated into HCC1937 cells. 
The cassette contains two I-SceI recognition sequences 
flanking an ATG initiation codon and has been 
described previously [1]. Forty-eight hours after HD-Ad 
infection, cells were infected with Ad-SceI and 
harvested at 0, 8, 16, or 24 h after Ad-SceI infection for 
DNA isolation. NHEJ events were determined by qPCR 
performed on an ABI 7900HT real-time PCR 
instrument using SYBR Green master mix (ABI). 
Relative NHEJ levels were determined after 
normalizing to β-actin. The PCR primers used were 5'-
CACGAGACTAGCCTCGAGGTTT-3' and 5'-





Trypan Blue/FACS cell-survival assay. HCC1937 cells 
were infected with HD-Ad vectors on 100 mm dishes. 
Forty-eight hours after infection, cells were trypsinized 
and 250,000 cells were seeded onto 60 mm dishes. 
Twenty-four hours after seeding, cells were irradiated 
with either 4 or 8 Gy or left unirradiated. Seven days 
after irradiation, the total number of cells in each dish 
were collected and re-suspended in equal volumes of 
media. Trypan Blue was added to the samples 
immediately prior to fluorescence-activated cell sorting 
(FACS) analysis as described [2].    
 
Cell cycle analysis. HCC1937 cells were serum-starved, 
infected with HD-Ad vectors, and cells collected at 8, 
16, 24, or 48 h after infection were fixed in 70% ethanol 
and cell-cycle distribution was analyzed by propidium 
iodide staining and FACS as described [3]. 
 
Scoring of human breast cancer tissue sections. Scoring 
of immunohistochemical stained sections was 
performed at Anatomic Pathology Research Services, 
Department of Pathology, Virginia Commonwealth 
University by a pathologist (M.O.I.) blinded to the 
study whose clinical specialty is breast pathology. 
Briefly, slides were reviewed using a Nikon Eclipse 80i 
light microscope and evaluated to ensure the presence 
of infiltrating and/or in situ carcinoma. Areas of fat 
necrosis or previous biopsy related changes were 
excluded from the evaluation as well as the edge of 
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